Article info
PDFPostScript
Letter
Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study
- Correspondence to Professor Gary Tse, Tianjin Institute of Cardiology, Tianjin Medical University, Tianjin 300070, China; garytse86{at}gmail.com; Professor Qingpeng Zhang, School of Data Science, City University of Hong Kong, Hong Kong, China; qingpeng.zhang{at}cityu.edu.hk
Citation
Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study
Publication history
- Received November 19, 2020
- Revised November 23, 2020
- Accepted November 29, 2020
- First published December 4, 2020.
Online issue publication
January 10, 2022
Article Versions
- Previous version (8 January 2022).
- Previous version (8 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage